CanSino Biologics, Inc. Class H (HK:6185)
:6185
Want to see HK:6185 full AI Analyst Report?
6185 Stock Chart & Stats
HK$44.94
-HK$0.10(-0.36%)
At close: 4:00 PM EST
HK$44.94
-HK$0.10(-0.36%)
Day’s Range― - ―
52-Week RangeHK$22.14 - HK$56.55
Previous CloseN/A
Volume470.05K
Average Volume (3M)609.75K
Market Cap
HK$9.89B
Enterprise ValueHK$10.73B
Total Cash (Recent Filing)HK$2.07B
Total Debt (Recent Filing)HK$1.16B
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding132,670,900
10 Day Avg. Volume458,410
30 Day Avg. Volume609,752
Financial Highlights & Ratios
PEG Ratio-2.73
Price to Book (P/B)1.60
Price to Sales (P/S)7.70
P/FCF Ratio-52.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$1.43B
Bulls Say, Bears Say
Bulls Say
Integrated Vaccine R&D-to-commercializationCanSino's vertically integrated vaccine model—covering R&D through manufacturing and commercialization—allows it to capture more value across the product lifecycle, accelerate scale-up for approved vaccines, maintain quality control, and better compete for public procurement over multiple quarters.
Moderate Leverage / Solid Balance SheetA debt-to-equity near 0.26 and a sizeable equity base provide financial flexibility, lowering refinancing risk and supporting sustained R&D and capacity investments. This balance sheet strength helps absorb short-term shocks and funds multi-quarter product development and manufacturing scale-up.
Recent Strong Revenue GrowthReported revenue growth of roughly 31% indicates improving commercial traction, likely from product sales or procurement wins. If this trend persists, it supports scale economies, better absorption of fixed manufacturing costs, and a clearer path to sustained margin improvement over several quarters.
Bears Say
Fragile ProfitabilityThough performance has improved from earlier heavy losses, TTM still shows a slight net loss and negative operating profit. Fragile earnings quality raises the risk that profitability can reverse, forcing cost cutting or external capital that could disrupt long-term R&D and commercialization plans.
Negative Free Cash FlowFree cash flow remains negative despite improving operating cash flow, meaning the company still burns cash after investments. Persistent negative FCF pressures liquidity, increases reliance on external funding, and can constrain long-term investment in capacity or pipeline progression.
Low Returns On Equity / Profit VolatilityROE near 0.6% shows the company is not yet converting capital into meaningful returns. Combined with multi-year swings from high profitability to deep losses, low ROE and volatility weaken durable earnings power and make sustained shareholder value creation uncertain over upcoming quarters.
CanSino Biologics, Inc. Class H News
6185 FAQ
What was CanSino Biologics, Inc. Class H’s price range in the past 12 months?
CanSino Biologics, Inc. Class H lowest stock price was HK$22.14 and its highest was HK$56.55 in the past 12 months.
What is CanSino Biologics, Inc. Class H’s market cap?
CanSino Biologics, Inc. Class H’s market cap is HK$9.89B.
When is CanSino Biologics, Inc. Class H’s upcoming earnings report date?
CanSino Biologics, Inc. Class H’s upcoming earnings report date is Aug 21, 2026 which is in 66 days.
How were CanSino Biologics, Inc. Class H’s earnings last quarter?
CanSino Biologics, Inc. Class H released its earnings results on Apr 28, 2026. The company reported -HK$0.184 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.184.
Is CanSino Biologics, Inc. Class H overvalued?
According to Wall Street analysts CanSino Biologics, Inc. Class H’s price is currently Overvalued.
Does CanSino Biologics, Inc. Class H pay dividends?
CanSino Biologics, Inc. Class H pays a Notavailable dividend of HK$0.937 which represents an annual dividend yield of N/A. See more information on CanSino Biologics, Inc. Class H dividends here
What is CanSino Biologics, Inc. Class H’s EPS estimate?
CanSino Biologics, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CanSino Biologics, Inc. Class H have?
CanSino Biologics, Inc. Class H has 132,670,900 shares outstanding.
What happened to CanSino Biologics, Inc. Class H’s price movement after its last earnings report?
CanSino Biologics, Inc. Class H reported an EPS of -HK$0.184 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.805%.
Which hedge fund is a major shareholder of CanSino Biologics, Inc. Class H?
Currently, no hedge funds are holding shares in HK:6185
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CanSino Biologics, Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.91%
12-Months-Change
Fundamentals
Return on Equity
-0.02%
Trailing 12-Months
Asset Growth
-5.44%
Trailing 12-Months
Company Description
CanSino Biologics, Inc. Class H
CanSino Biologics Inc., a company established in 2009 and headquartered in Tianjin, People's Republic of China, is dedicated to the research, development, manufacturing, and commercialization of vaccines throughout China. Its existing portfolio includes significant vaccines such as Convidecia and Ad5-nCoV for Inhalation, both designed to combat recombinant novel coronavirus disease. The company has also developed Ad5-EBOV, an effective vaccine against the Ebola virus, and offers MCV2 and MCV4 vaccines for preventing N. meningitides infections. A substantial portion of its pipeline is currently undergoing Phase I clinical trials. This includes DTcP vaccines for infants and a DTcP Booster, both aimed at providing enhanced protection against pertussis after initial immunization. Also in Phase I are PBPV, a serotype-independent protein-based pneumococcal vaccine; PCV13i, a pneumococcal conjugate vaccine; and a TB Booster vaccine intended for the BCG-immunized population. Furthermore, CanSino is developing a Tdcp vaccine specifically for adolescents and adults to address pertussis. Beyond these clinical-stage candidates, the company maintains a robust pipeline of preclinical products. This includes a DTcP-Hib Combo vaccine, CSB012 for adenovirus, CSB013 targeting the ZIKA virus, CSB015 for meningitis, CSB016 for shingles, and CSB107 against polio.
Technical Analysis
HUTCHMED (China)
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Ab&B Bio-Tech CO., LTD. JS Class H
―
Xuanzhu Biopharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---